Literature DB >> 3124284

Tissue plasminogen activator and urokinase in normal, dysplastic and cancerous squamous epithelium of the uterine cervix.

G Larsson1, A Larsson, B Astedt.   

Abstract

The distribution of tissue plasminogen activator (t-PA) and urokinase (u-PA) was investigated immunohistochemically in squamous epithelium of the uterine cervix, in normal and dysplastic conditions as well as in preinvasive and invasive carcinomas. Normal epithelium showed presence of both t-PA and u-PA immunoreactivity only in the superficial cellular layer, whereas in preinvasive lesions they were present in all layers. In sections of normal specimens as well as preinvasive lesions the UK immunoreactivity was weaker compared to that of t-PA. Invasive lesions showed a patchy distribution of t-PA and u-PA immunoreactivity. Furthermore, it could be demonstrated that stromal cells close to the infiltrating malignant squamous epithelium contained t-PA immunoreactivity and also u-PA immunoreactivity. Further immunohistochemical studies disclosed that these cells were macrophages.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3124284

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.

Authors:  H Kobayashi; H Shinohara; H Ohi; M Sugimura; T Terao; M Fujie
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

2.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

Authors:  C F Sier; H W Verspaget; G Griffioen; S Ganesh; H J Vloedgraven; C B Lamers
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

3.  XH1--a new cervical carcinoma cell line and xenograft model of tumour invasion, 'metastasis' and regression.

Authors:  X Han; R Lyle; D L Eustace; R J Jewers; J M Parrington; A Das; T Chana; B Dagg; S Money; T D Bates
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.